摘要
Prostate cancer remains one of the most prevalent malignancies in men globally(Preisser et al.2020).Accurate diagnosis and diferentiation of the disease are paramount for efective treatment planning and improved patient outcomes(Hsieh et al.2022).Traditionally,the diagnosis of prostate cancer heavily relied on invasive biopsy procedures,which,although efective,are associated with potential complications and discomfort for patients.With the advancements in medical imaging,positron emission tomography/computed tomography(PET/CT)using prostate-specifc membrane antigen(PSMA)tracers has emerged as a revolutionary diagnostic tool(Obek et al.2017).This technique,often termed as'virtual biopsy',provides a non-invasive alternative to traditional biopsy.Baseline PSMA PET/CT ofers detailed and precise imaging of prostate lesions,allowing clinicians to pinpoint not only the location but also the potential aggressiveness of the tumor.The capability of PSMA PET/CT to bind specifcally to PSMA-expressing cells gives it a unique edge in diferentiating between benign and malignant prostate lesions.
